PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

PURPOSE: Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance. PATIENTS AND METHODS: Tumors from patients with...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Janku, Filip, Wheler, Jennifer J., Westin, Shannon N., Moulder, Stacy L., Naing, Aung, Tsimberidou, Apostolia M., Fu, Siqing, Falchook, Gerald S., Hong, David S., Garrido-Laguna, Ignacio, Luthra, Rajyalakshmi, Lee, J. Jack, Lu, Karen H., Kurzrock, Razelle
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2012
Materias:
Original Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3295566/
https://ncbi.nlm.nih.gov/pubmed/22271473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.36.1196
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares